Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Decreases By 13.4%

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a large decline in short interest in November. As of November 15th, there was short interest totalling 44,100 shares, a decline of 13.4% from the October 31st total of 50,900 shares. Based on an average daily volume of 44,300 shares, the short-interest ratio is presently 1.0 days. Approximately 2.4% of the company’s stock are sold short.

Institutional Investors Weigh In On Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC acquired a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned about 1.17% of Avenue Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 17.34% of the company’s stock.

Avenue Therapeutics Stock Performance

Shares of ATXI stock opened at $1.94 on Tuesday. The company has a market capitalization of $3.71 million, a price-to-earnings ratio of 0.12 and a beta of -0.17. Avenue Therapeutics has a one year low of $1.60 and a one year high of $26.47. The company’s 50-day moving average is $2.15 and its 200 day moving average is $2.80.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.